|
Safety
Possible side effects include stomach
irritation, anxiety, irritability and insomnia.
Pregnant and breast-feeding women are advised to consult
their healthcare practitioner before using CF Support.
This product is not suitable for
persons allergic to bovine products. There
is no known drug interaction.
Suggested Use
As a dietary supplement, take one bottle of NatCell®
CF Support per day. Start with CF Supportl
for 8 days, then CF Support2 for 8 days and finish
the cycle with CF Support1 for 8 days. CF
Support1 contains 5.6 ml of bovine mesenchyme aqueous
extract, and 1.4 ml of bovine adrenal aqueous extract.
CF Support2 contains 3.5 ml of bovine mesenchyme
aqueous extract, and 3.5 ml of bovine adrenal aqueous
extract. Serving size: 1 bottle of 7 ml.
References
-
Behan WM, More IA, Behan PO., Mitochondrial
abnormalities in the postviral fatigue syndrome.
Acta Neuropathol (Berl). 1991;83(1):61-5.
-
Bennett RM, Adult growth hormone
deficiency in patients with fibromyalgia. Curr Rheumatol
Rep. 2002 Aug;4(4):306-12. Review
-
Berwaerts J, Moorkens G, Abs R.,
Secretion of growth hormone in patients with chronic
fatigue syndrome. Growth Horm IGF Res. 1998 Apr;8
Suppl B:127-9.
-
Buchwald D, Herrell R, Ashton S,
Belcourt M, Schmaling K, Sullivan P, Neale M, Goldberg
J., A twin study of chronic fatigue. Psychosom Med,
2001 Nov-Dec;63(6):936-43.
-
Craveri F, De Pascale V., Activity
of orally administered adrenocortical extract. 1.
Effect on the survival test. Boll Chim Farm 1971;110:457-62.
-
Craveri F, De Pascale V., Activity
of orally administered adrenocortical extract. II.
Effect on liver glycogenesis and sodium retention.
Boll Chim Farm 1971;110:457-62.
-
Craveri F, De Pascale V., Activity
of orally administered adrenocortical extract. III.
Effect in tests based on muscular work. Boll Chim
Farm 1971; 110: 457-62.
-
DeMeirleir K, Bisbal C, Campine I,
De Becker, P, Salehzada, T, Demettre, E and Lebleu,
BA., A 37 kDa 25A binding protein as a potential biochemical
marker for chronic fatigue syndrome. Am J Med, 2000;
(108);99-105
-
Demitrack MA Crofford W., Evidence
for and pathophysiologic implications of hypothalamicpituitary-adrenal
axis dysregulation in fibromyalgia and chronic fatigue
syndrome. Ann N Y Acad Sci. 1998 May 1;840:684-97.
Review.
-
Dowsett EG, Ramsay AM, McCartney
RA, Bell EJ., Myalgic encephalomyelitis--a persistent
enteroviral infection? Postgrad Med J. 1990 Jul;66(777):526-30.
-
Farrar DJ, Locke SE, Kantrowitz FG,
Chronic Fatigue Syndrome.1: Etiology and Pathogenesis
Behavioral Medicine, 1995; 21 (1): 5-16
-
Fulle S, Mecocci P, Fano G, Vecchiet
I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo
E, Vecchiet L, Senin U, Beal MF., Specific oxidative
alterations in vastus lateralis muscle of patients
with the diagnosis of chronic fatigue syndrome. Free
Radic Biol Med. 2000 Dec 15;29(12):1252-9.
-
Gaab J, Huster D, Peisen R, Engert
V, Schad T, Schurmeyer TH, Ehlert U, Low-dose dexamethasone
suppression test in chronic fatigue syndrome and health.
Psychosom Med. 2002 Mar-Apr;64(2):311-8.
-
Ho-Yen DO,
McNamara I., General practitioners' experience of
the chronic fatigue syndrome. Br J Gen Pract. 1991;
Aug;41(349):324-6.
-
Katon W, Walker E., The relationship of chronic fatigue
to psychiatric illness in community, primary care
and tertiary care samples.- Chronic fatigue syndrome-
New York: Wiley, John & Sons Inc. 1993, Ciba Foundation
Symposia Series; no 173: 193-211
-
Keller RH, Lane JL, Klimas N, Reiter WM, Fletcher
MA, van Riel F, Morgan R., Association of HLA class
II antigens and chronic fatigue immune dysfunction
syndrome. Clin Infect Dis, 1994; (18): S154-6
-
Klein R, Berg PA, High incidence of antibodies to
5-hydroxy-tryptamine, gangliosides and phospholipids
in patients with chronic fatigue and fibromyalgia
syndrome and their relatives: evidence for a clinical
entity of both disorders. Eur J Med Res, 1995; (1):21-6
-
Landay AL, Jessop C, Lennette ET, Levyk JA, Chronic
Fatigue Syndrome: clinical condition associated with
immune activation. Lancet, 1991; (338) no 8769:707-12
-
Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R,
Archard LC., Muscle fibre characteristics and lactate
responses to exercise in chronic fatigue syndrome.
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):362-7.
-
Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough
G, Herberman RB, Dysfunction of natural killer activity
in a family with chronic fatigue syndrome. Clin Immunol
Immunopathol, 1998; (88):96-104
-
Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva
H, Garcia-Pesquera F, Casanueva FF, Dieguez C., The
growth hormone (GH)-releasing hormone-GH-insulin-like
growth factor-1 axis in patients with fibromyalgia
syndrome. J Clin Endocrinol Metab. 1999 Sep;84(9):3378-81.
-
Logan AC, Wong C., Chronic fatigue syndrome: oxidative
stress and dietary modifications. Altern Med Rev.
2001 Oct;6(5):450-9. Review.
-
MacHale SM, Cavanagh JT, Bennie J, Carroll S, Goodwin
GM, Lawrie SM., Diurnal variation of adrenocortical
activity in chronic fatigue syndrome. Neuropsychobiology.
1998 Nov;38(4):213-7.
-
Manian FA, Simultaneous measurement of antibodies
to Epstein-Barr virus, human herpesvirus 6, herpes
simplex virus types 1 and 2, and 14 enteroviruses
in chronic fatigue syndrome: is there evidence of
activation of a nonspecific polyclonal immune response?
Clin Infect Dis. 1994 Sep;19(3):448-53.
-
McCully KK, Natelson BH, Iotti S, Sisto S, Leigh JS
Jr., Reduced oxidative muscle metabolism in chronic
fatigue syndrome. Muscle Nerve. 1996 May; 19(5):621-5.
-
Niehans P., Introduction
to cellular therapy. New York, NY. Pageant books, 1960.
-
Ottenweller JE, Sisto SA, McCarty RC, Natelson BH.,
Hormonal responses to exercise in chronic fatigue
syndrome. Neuropsychobiology. 2001 Jan;43(l):34-41.
-
Richards RS, Roberts TK, McGregor NR, Dunstan RH,
Butt HL., Blood parameters indicative of oxidative
stress are associated with symptom expression in chronic
fatigue syndrome. Redox Rep. 2000;5(l):35-41.
-
Shepherd C., Hydrocortisone and chronic fatigue syndrome.
Lancet. 1999 May 8;353(9164):161920.
-
Scott LV, Teh J, Reznek R, Martin A, Sohaib A, Dinan
TG, Small adrenal glands in chronic fatigue syndrome:
a preliminary computer tomography study. Psychoneuroendocrinology,
1999; (24): 75968
-
Scott LV, Medbak S, Dinan TG., Blunted adrenocorticotropin
and cortisol -responses to cortocotropic-releasing
hormone stimulation in chronic fatigue syndrome. Acta
Psychiatr Scand 1998;97:450-457.
-
US Department of Health and Human Services. National
Center for Infectuous diseases. Centers for Disease
Control and Prevention. The facts about chronic fatigue
syndrome, Atlanta, GA, 1995.
-
Walsh CM, Zainal NZ, Middleton SJ, Paykel ES., A family
history study of chronic fatigue syndrome. Psychiatr
Genet, 2001; Sep;11(3):123-8.
-
Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J.,
Serotonin levels, pain threshold, and fibromyalgia
symptoms in the general population. J Rheumatol, 1997;
(24):555-9
|
